Serenex, Inc. announced the signing of a research agreement with Roche which involves the utilization of Serenex’ novel chemoproteomics technologies within Roche’s drug discovery program. The companies will jointly evaluate how Serenex’ technologies may impact the identification of the most appropriate compounds to advance through drug discovery and development Richard S. Kent, M.D., President and Read more about Roche And Serenex Sign Agreement[…]